Skip to content
Triangle logo TriangleGet started
← Childhood Vascular Tumors

HEALTH PROFESSIONAL · SOURCE READING

Treatment of complicated kaposiform hemangioendothelioma and tufted angioma

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Intermediate Tumors (Locally Aggressive) / Kaposiform Hemangioendothelioma and Tufted Angioma / Treatment of kaposiform hemangioendothelioma and tufted angioma

Patients who have Kasabach-Merritt phenomenon and/or functional compromise and are symptomatic need aggressive therapy. An American and Canadian multidisciplinary expert panel published guidelines for the management of complicated kaposiform hemangioendotheliomas.[21] A number of treatment therapies have been reported but none have been uniformly effective.[22,23]

Source links and citations

Treatment options for complicated kaposiform hemangioendotheliomas and Kasabach-Merritt phenomenon include the following:

Vincristine with or without steroid therapy.

Source links and citations

Sirolimus with or without steroid therapy.

Source links and citations

Surgical excision.

Source links and citations

Continue within this section

Vincristine with or without steroid therapy →Sirolimus with or without steroid therapy →Supportive care and close monitoring of infants on sirolimus →Surgical excision →Long-term outcomes →

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice